This site is intended for healthcare professionals
Anticoagulation Therapy for Stroke Prevention

Expert Opinion

Read time: 10 mins
Last updated:24th Nov 2021
Published:24th Nov 2021

Stroke Prevention: Watch Interviews from ESC 2019

We spoke to two of the leading experts in their field to get the latest on the changing treatment landscape for stroke prevention in patients with atrial fibrillation and ACS and/or PCI, and learn details of the ground-breaking AUGUSTUS trial.
Choose one of the links below to open a series of video interviews with leading stroke prevention experts Professor Renato Lopes and Professor Robert Storey filmed at the ESC Congress 2019 in Paris, France (31 August–4 September). 

Professor Storey answered questions around the unmet need that still exists for patients with atrial fibrillation and acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and the changing treatment landscape. He also gave us his opinion on the current US and European guidelines and advice for interpreting real world data.

Professor Lopes, principal investigator of the AUGUSTUS trial, answered questions about AUGUSTUS, the subsequent meta-analysis and the ENTRUST study. He told us why AUGUSTUS was such an impactful trial in highlighting the dangers of using aspirin and triple therapy for stroke prevention in patients with atrial fibrillation and ACS and/or PCI.  

Nomenclature: DOACs are also known as novel or non-vitamin K anticoagulants (NOAC). However, there is a possibility that a healthcare professional might mistake NOAC for ‘no anticoagulants’ with potentially serious or even life-threatening consequences. NOACs are referred to in the expert opinion videos.